Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Published online: 04 January 2019; doi:10.1038/s41573-018-0008-x

The transcription factor NRF2 and its repressor KEAP1 have been implicated in the development and progression of chronic diseases. Here, Dinkova-Kostova and colleagues provide an overview of the physiological and pathological roles of NRF2, present emerging pharmacological modulators of the NRF2–KEAP1 axis and highlight associated drug development challenges.

Articles You May Like

Are there Zika reservoirs in the Americas?
Guardians of the synapse: Scientists identify a new role for nerve-supporting cells
Green tea cuts obesity, health risks in mice
Making xylitol and cellulose nanofibers from paper paste
Massive U.S. Machines That Hunt For Ripples In Space-Time Just Got An Upgrade

Leave a Reply

Your email address will not be published. Required fields are marked *